CVAC CureVac N.V.

Nasdaq curevac.com


$ 5.39 $ -0.03 (-0.56 %)    

Thursday, 16-Oct-2025 15:59:59 EDT
QQQ $ 598.03 $ -2.23 (-0.37 %)
DIA $ 458.47 $ -3.15 (-0.68 %)
SPY $ 658.59 $ -4.53 (-0.68 %)
TLT $ 91.44 $ 0.68 (0.75 %)
GLD $ 400.31 $ 9.06 (2.34 %)
$ 5.37
$ 5.41
$ 5.31 x 290
$ 5.47 x 4
$ 5.34 - $ 5.41
$ 2.37 - $ 5.72
648,223
na
1.2B
$ 1.44
$ 7.18
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 curevac-reports-q2-revenues-of-eur12m-lower-than-eur144m-yoy

The decrease year-over-year was primarily driven by lower revenues from GSK following the restructuring of the partnership in J...

Core News & Articles

Under the terms of the agreements, CureVac and GSK will receive in aggregate a payment of $740 million as well as single-digit ...

 biontech-narrows-losses-q2-revenue-doubles-as-vaccine-collaboration-drives-growth

BioNTech beat Q2 estimates with higher COVID vaccine revenue and reaffirmed 2025 guidance.

 ubs-downgrades-curevac-to-neutral-lowers-price-target-to-55

UBS analyst Eliana Merle downgrades CureVac (NASDAQ:CVAC) from Buy to Neutral and lowers the price target from $12 to $5.5.

 jefferies-downgrades-curevac-to-hold-lowers-price-target-to-5

Jefferies analyst Roger Song downgrades CureVac (NASDAQ:CVAC) from Buy to Hold and lowers the price target from $7 to $5.

 biontech-expands-mrna-cancer-portfolio-with-curevac-125-billion-all-stock-deal

BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.

Core News & Articles

Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy c...

 trump-administration-terminates-590-million-moderna-bird-flu-vaccine-deal-dismantling-biden-era-pandemic-preparedness-effort

The Trump administration terminated a nearly $600 million award to Moderna for developing an mRNA-based bird flu vaccine, endin...

 jmp-securities-reiterates-market-outperform-on-curevac-maintains-10-price-target

JMP Securities analyst Roy Buchanan reiterates CureVac (NASDAQ:CVAC) with a Market Outperform and maintains $10 price target.

 curevac-cvac-stock-rises-after-q1-update-oncology-pipeline-gains-traction

CureVac stock surged after reporting Q1 2025 results and a positive pipeline update. The biotech firm narrowed its operating lo...

 curevac-q1-sales-94645k-miss-334m-estimate-company-exits-quarter-with-cash-and-equivalents-worth-46091m

CureVac reaffirmed expected cash runway into 2028,

 ubs-maintains-buy-on-curevac-lowers-price-target-to-12

UBS analyst Eliana Merle maintains CureVac (NASDAQ:CVAC) with a Buy and lowers the price target from $13 to $12.

 curevac-q4-sales-1450m-may-not-be-comparable-to-650m-estimate

CureVac (NASDAQ:CVAC) reported quarterly sales of $14.50 million which beat the analyst consensus estimate of $6.50 million by ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION